Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inexpensive Diagnostic Device May Revolutionize Medical Care

By LabMedica International staff writers
Posted on 28 Feb 2017
A radically designed “lab on a chip” diagnostic device is expected to dramatically reduce the cost of isolating and characterizing rare cells and molecules, a process that is of critical importance in diagnosis of common lethal diseases such as malaria, tuberculosis, HIV, and cancer.

Point-of-care diagnostics in the developing world and resource-limited areas require numerous special design considerations to provide effective early detection of disease. More...
Of particular need for these contexts are diagnostic technologies featuring low costs, ease of use, and broad applicability. Investigators at Stanford University recently described a nanoparticle-inkjet-printable microfluidics-based platform that fulfilled these criteria and that is expected to significantly reduce the footprint, complexity, and cost of clinical diagnostics. This reusable 0.01 USD device is miniaturized to handle small sample volumes and can perform numerous analyses.

The device is a combination of microfluidics, electronics, and inkjet printing technology. It is in essence a two-part system: a clear silicone microfluidic chamber for housing cells resting on top of a reusable electronic strip. A regular inkjet printer was used to print the electronic strip onto a flexible sheet of polyester using commercially available conductive nanoparticle ink.

The device, which separates cells based on their size and intrinsic electrical properties, can perform label-free and rapid single-cell capture, efficient cellular manipulation, rare-cell isolation and selective analytical separation of biological species, sorting, concentration, positioning, enumeration, and characterization. The miniaturized format allows for small sample and reagent volumes. By keeping the electronics separate from microfluidic chips, the former can be reused and device lifetime is extended.

The process of manufacturing the device is significantly less expensive, time-consuming, and complex than traditional lab-on-a-chip platforms, requiring only an inkjet printer rather than skilled personnel and clean-room facilities. Production requires only about 20 minutes (versus up to weeks) and one US cent - an unprecedented cost in in clinical diagnostics.

“The genome project has changed the way an awful lot of medicine is done, and we want to continue that with all sorts of other technology that are just really inexpensive and accessible,” said senior author Dr. Ronald W. Davis, professor of biochemistry and genetics at Stanford University. “The motivation was really how to export technology and how to decrease the cost of things.”

A study describing the technology was published in the February 6, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.